NCT05911295 2026-04-20
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Phase 3 Active not recruiting
Seagen Inc.
BeOne Medicines
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Hoffmann-La Roche
Mabwell (Shanghai) Bioscience Co., Ltd.
RemeGen Co., Ltd.
National Cancer Institute (NCI)
Shanghai Junshi Bioscience Co., Ltd.
Association of Urologic Oncology (AUO)